Holen Sie sich die Stockscreener-App
5.155
2.08%
0.105
Handel nachbörslich:
5.09
-0.065
-1.26%
Schlusskurs vom Vortag:
$5.05
Offen:
$4.99
24-Stunden-Volumen:
4.79M
Relative Volume:
0.85
Marktkapitalisierung:
$1.41B
Einnahmen:
$8.10M
Nettoeinkommen (Verlust:
$-92.72M
KGV:
-15.16
EPS:
-0.34
Netto-Cashflow:
$-82.52M
1W Leistung:
+9.22%
1M Leistung:
+67.92%
6M Leistung:
+302.73%
1J Leistung:
+159.05%
1-Tages-Spanne:
$4.80
$5.16
1-Wochen-Bereich:
$4.67
$5.21
52-Wochen-Spanne:
$1.05
$5.40
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Firmenname
Taysha Gene Therapies Inc
Sektor
Branche
Telefon
(214) 612-0000
Adresse
3000 PEGASUS PARK DRIVE, DALLAS
Vergleichen Sie TSHA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
5.155 | 1.38B | 8.10M | -92.72M | -82.52M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-11 | Eingeleitet | BofA Securities | Buy |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-04-09 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-01 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-03-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-03-01 | Eingeleitet | Wells Fargo | Overweight |
| 2022-02-18 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | Guggenheim | Buy |
| 2021-07-16 | Eingeleitet | Needham | Buy |
| 2021-06-24 | Eingeleitet | Truist | Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-06-09 | Eingeleitet | Wedbush | Outperform |
| 2021-06-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Fortgesetzt | Jefferies | Buy |
| 2021-02-24 | Eingeleitet | William Blair | Outperform |
| 2021-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-19 | Eingeleitet | Goldman | Buy |
| 2020-10-19 | Eingeleitet | Jefferies | Buy |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten
Why Taysha Gene Therapies Inc. is moving todayTrade Entry Summary & Long Hold Capital Preservation Tips - newser.com
Why Taysha Gene Therapies Inc. stock is favored by top institutions2025 Trading Volume Trends & Weekly Top Gainers Alerts - newser.com
Taysha Gene Therapies stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Earnings visualization tools for Taysha Gene Therapies Inc.Weekly Trading Summary & Fast Entry Momentum Trade Alerts - newser.com
Has Taysha Gene Therapies Inc. formed a bullish divergenceJuly 2025 Decliners & Low Drawdown Investment Strategies - newser.com
Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory - MSN
Tick level data insight on Taysha Gene Therapies Inc. volatilityJuly 2025 Sentiment & Free Reliable Trade Execution Plans - newser.com
What MACD and RSI say about Taysha Gene Therapies Inc.2025 Volume Leaders & Smart Allocation Stock Tips - newser.com
Can Taysha Gene Therapies Inc. stock hit record highs again2025 Volatility Report & Verified Entry Point Signals - newser.com
Is Taysha Gene Therapies Inc. trending in predictive chart modelsPortfolio Return Report & Consistent Income Trade Ideas - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Taysha Gene Therapies Hits Day High with 7.2% Surge in Stock Price - Markets Mojo
Taysha Gene Therapies (TSHA) Reveals Enhanced Trial Results for Rett Syndrome - GuruFocus
Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting - The Manila Times
Taysha Gene Therapies Presents New Supplemental Data - GlobeNewswire
Taysha's TSHA-102 Shows 100% Response in Phase 1/2 Rett Trial | TSHA Stock News - Stock Titan
Will Taysha Gene Therapies Inc. stock continue dividend increasesMarket Sentiment Summary & Technical Entry and Exit Tips - newser.com
Analyzing net buyer seller activity in Taysha Gene Therapies Inc.Weekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com
Visual analytics tools that track Taysha Gene Therapies Inc. performanceEarnings Beat & Daily Technical Stock Forecast Reports - newser.com
Taysha Gene Therapies Hits Day Low of $4.40 Amid Price Pressure - Markets Mojo
Taysha Gene Therapies, Inc. Sees Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Taysha soars on FDA breakthrough therapy status for lead asset - MSN
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9%Time to Sell? - MarketBeat
Taysha Gene Therapies Hits New 52-Week High at $5.40 - Markets Mojo
Taysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration Potential (TSHA) - Seeking Alpha
Will Taysha Gene Therapies Inc. stock maintain growth story2025 Trading Volume Trends & Fast Moving Market Watchlists - newser.com
How to interpret RSI for Taysha Gene Therapies Inc. stockWeekly Trade Analysis & Low Volatility Stock Recommendations - newser.com
Taysha Snags FDA Breakthrough Therapy Designation for Rett Syndrome Gene Therapy TSHA-102 - CGTLive®
How Recent Developments Are Rewriting the Story for Taysha Gene Therapies - Yahoo Finance
Taysha Gene Therapies (TSHA) Gets a Buy from Canaccord Genuity - The Globe and Mail
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Needham & Company LLC Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price - Defense World
Best Small Cap Stocks To Add to Your Watchlist – October 2nd - Defense World
Taysha Gene Therapies stock hits 52-week high at 5.05 USD - Investing.com Nigeria
1.29M-option grant: Taysha grants 1,289,600 stock options at $3.18, 4-yr vesting under Nasdaq rule - Stock Titan
US FDA Backing Is A Breakthrough For Taysha’s Gene Therapy - insights.citeline.com
Taysha Gene Therapies (NASDAQ:TSHA) Sees Unusually-High Trading Volume After Analyst Upgrade - MarketBeat
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $8 to $14 - 富途牛牛
Taysha Gene Therapies Announces January 2022 Virtual Investor Events to Review Preliminary Clinical Data for TSHA-101 in GM2 Gangliosidosis and High Dose Cohort and Long-Term Clinical Data for TSHA-120 in Giant Axonal Neuropathy | FinancialCont - FinancialContent
Taysha Gene Therapies Stock Soars To 3-Year High After FDA Boost — Wall Street Calls Rett Drug ‘Derisked’ And Ahead Of Rivals - Stocktwits
Could Taysha's FDA Alignment Fast-Track Its BLA Submission? - RTTNews
Robert W. Baird Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price - Defense World
Analyzing drawdowns of Taysha Gene Therapies Inc. with statistical toolsJuly 2025 Big Picture & Smart Allocation Stock Tips - newser.com
Finanzdaten der Taysha Gene Therapies Inc-Aktie (TSHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Taysha Gene Therapies Inc-Aktie (TSHA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D |
Sep 10 '25 |
Option Exercise |
0.70 |
41,150 |
28,760 |
1,206,439 |
| Nagendran Sukumar | President and Head of R&D |
Sep 10 '25 |
Sale |
3.23 |
200,000 |
646,000 |
1,006,439 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):